Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2013 by CTI BioPharma.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
CTI BioPharma
ClinicalTrials.gov Identifier:
First received: February 5, 2003
Last updated: July 29, 2013
Last verified: July 2013

February 5, 2003
July 29, 2013
January 2003
December 2013   (final data collection date for primary outcome measure)
Saftey [ Time Frame: Baseline to end of treatment ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00054184 on ClinicalTrials.gov Archive Site
Efficacy [ Time Frame: Basline to EOS ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether polyglutamate paclitaxel is more effective than docetaxel in treating non-small cell lung cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel with that of docetaxel in treating patients who have progressive non-small cell lung cancer.


  • Compare the efficacy of polyglutamate paclitaxel (CT-2103) vs docetaxel as second-line therapy, in terms of duration of overall survival, in patients with progressive non-small cell lung cancer.
  • Compare the safety and toxicity of these regimens in these patients.
  • Compare the disease control (stable disease maintained for at least 12 weeks, partial response, or complete response) and progression-free survival of patients treated with these regimens.
  • Compare the improvement in lung cancer symptoms in patients treated with these regimens.
  • Compare the frequency of grade 3 and 4 neurotoxicity, edema, alopecia, and side effects related to corticosteroids in patients treated with these regimens.
  • Determine the percentage of patients who receive at least 4 courses of study treatment.
  • Compare the response rate in patients with measurable disease treated with these regimens.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to stage (IV vs other), performance status (0 or 1 vs 2), start of front-line chemotherapy from randomization (less than 16 weeks vs at least 16 weeks), gender, and prior taxane therapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive polyglutamate paclitaxel (CT-2103) IV over 10 minutes on day 1.
  • Arm II: Patients receive docetaxel IV over 1 hour on day 1. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed at 3 weeks and then every 8 weeks thereafter.

PROJECTED ACCRUAL: A total of 840 patients (420 per treatment arm) will be accrued for this study within 18 months.

Phase 3
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Lung Cancer
  • Drug: docetaxel
  • Drug: paclitaxel poliglumex
Experimental: Study drug
  • Drug: docetaxel
  • Drug: paclitaxel poliglumex
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
Not Provided
December 2013   (final data collection date for primary outcome measure)


  • Histologically confirmed non-small cell lung cancer (NSCLC)
  • Documented clinical or radiologic disease progression on or after initial systemic therapy

    • Must have received 1 prior platinum-based systemic therapy for NSCLC
  • Measurable or nonmeasurable disease
  • No evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell histology
  • Brain metastases allowed provided patient received prior standard antitumor therapy for CNS metastases (e.g., whole brain radiotherapy, stereotactic radioablation, or surgery) and the following conditions are met:

    • No prior systemic chemotherapy as a radiosensitizer combined with radiotherapy
    • Obtained stable neurologic function at least 2 weeks before study entry
    • Off steroid therapy or on a tapering regimen
    • Recovered from prior therapy



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Al least 16 weeks


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 2.5 times ULN
  • AST or ALT no greater than 1.5 times ULN


  • Creatinine no greater than 1.5 times ULN


  • No unstable angina
  • No myocardial infarction within the past 6 months
  • No evidence of cardiac conduction abnormalities (e.g., bundle branch block or heart block) unless cardiac status stable for the past 6 months


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No evidence of unstable neurological symptoms in the past 4 weeks (2 weeks for neurological symptoms due to brain metastases)
  • No intolerance to excipients of polyglutamate paclitaxel (e.g., poly-L-glutamic acid, poloxamer 188, dibasic sodium phosphate, or monobasic sodium hydroxide)
  • No other unstable medical conditions
  • No clinically significant active infection
  • No neuropathy greater than grade 1
  • No other concurrent primary malignancy except carcinoma in situ or nonmelanoma skin cancer
  • No circumstance that would preclude study completion or follow-up


Biologic therapy

  • Not specified


  • See Disease Characteristics
  • No prior polyglutamate paclitaxel
  • No prior docetaxel

Endocrine therapy

  • See Disease Characteristics


  • See Disease Characteristics
  • No concurrent radiotherapy


  • See Disease Characteristics
  • Recovered from prior major surgery


  • Recovered from prior therapy
  • More than 2 weeks since prior treatment for NSCLC
  • More than 4 weeks since prior investigational drugs
  • No other concurrent investigational drugs
  • No other concurrent systemic antitumor therapy
  • No concurrent amifostine
  • Concurrent bisphosphonates allowed
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
CTI-PGT302, CDR0000269907, CWRU-CTI-1503
Not Provided
Not Provided
Not Provided
CTI BioPharma
CTI BioPharma
Not Provided
Study Chair: Brenda Garrison PPD, Incorporated
CTI BioPharma
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP